New York, Feb 8, 2026, 17:03 EST — The market has closed.
Abbott Laboratories (ABT.N) finished Friday up 1.6% at $110.83, logging a second consecutive day of gains, yet still lagging the wider U.S. rally. Roughly 9.9 million shares changed hands—well above its 50-day average. Even so, Abbott’s price stayed about 22% under its 52-week peak of $141.23 set back on March 4 last year, according to MarketWatch data.
U.S. markets are shuttered until Monday, leaving investors to chew over whether the action sticks once trading’s back on. Abbott’s shares have lingered below their highs for months; lately, even modest news can spark swift shifts on the tape.
Director Daniel J. Starks picked up 10,000 shares of Abbott on Feb. 4, spending about $1.09 million, according to a Form 4 filing. The shares went for a weighted average between $108 and $109. Form 4s, filed with the U.S. Securities and Exchange Commission, disclose insider trades by top company officials and board members.
Abbott highlighted fresh data for its heart-rhythm devices at the AF Symposium in Boston, covering its Volt pulsed-field ablation system and the TactiFlex Duo catheter. The pulsed-field ablation process relies on electrical pulses to treat tissue responsible for irregular heartbeats. According to Abbott, the Volt trial delivered a 12-month freedom from rhythm recurrence rate of 84.2% among patients dealing with paroxysmal atrial fibrillation, the intermittent variety. “The data for Volt confirms what I see firsthand in the procedure room,” said Atul Verma, director of cardiology at McGill University Health Centre, in the company’s statement. Abbott MediaRoom
Friday brought some relief for investors following the latest tech slump, with nine out of the 11 S&P 500 sector indexes logging gains, according to Reuters.
Even with clinical results, translating those into sales isn’t always immediate—especially in the competitive medical-device space, where execution missteps get penalized fast. Insider buying? It’s often personal, inconsistent. And Abbott shares remain tied to rate moves and the market’s appetite for risk.
Abbott said in late January it was looking for organic sales growth between 6.5% and 7.5% in 2026, according to its press release. Adjusted diluted EPS? The company put that range at $5.55 to $5.80.
Looking ahead, Abbott’s quarterly dividend lands on Feb. 13, marking the next fixed event for shareholders. First though, ABT faces Monday’s session—traders watching to see if Friday’s rebound carries over, or if the stock slips back with the broader market.
